FloodLAMP FDA Deprioritization of COVID-19 Diagnostic EUAs (CDRH/OHT7) FDA CDRH/OHT7 deprioritization of COVID-19 diagnostic EUA submissions -- history, mechanics, emergence as a policy tool, comparison with 510(k) processes, prior emergency precedents, scale (558 EUA requests declined to review by Sept. 2021 per GAO), and independent analyses of transparency, resource constraints, and relationship to Omicron-era testing shortages. ai file regulatory fl-fda-correspondence _AI_FDA Deprioritization of COVID-19 Diagnostic EUAs.md regulatory/fl-fda-correspondence/_AI_FDA Deprioritization of COVID-19 Diagnostic EUAs.md 2026_03_02 Created by ChatGPT 5.2 Pro Extended during archive preparation. **NOT HUMAN VERIFIED - MAY CONTAIN ERRORS** Comprehensive analysis of FDA CDRH/OHT7's deprioritization practices for COVID-19 diagnostic EUA submissions, drawing from FDA's Booz Allen independent assessment, GAO-22-104266, FDA town hall transcripts, Food and Drug Law Journal analysis (Gibbs & Javitt), Reuters reporting, and ProPublica reporting. fda-deprioritization, eua, covid-diagnostics, cdrh, oht7, decline-to-review, gao md CC BY 4.0 - https://creativecommons.org/licenses/by/4.0/ 3272 5839 gfile-url xfile-github-download-url pdf-gdrive-url pdf-github-url github-markdown-url github-markdown-download-url web-pdf-url web-slides-url youtube-url web-url